Related Experiment Video

Updated: Sep 26, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

[Increased thrombin-genesis in cyclosporine A-treated idiopathic nephrotic syndrome in children]

Marcin Tkaczyk1, Danuta Owczarek, Michał Nowicki

  • 1Klinika Nefrologii i Dializoterapii Instytutu Centrum Zdrowia Matki Polki. iczmp.nefro@wp.pl

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|May 6, 2003
PubMed

Insights

Cyclosporine A (CsA) treatment for childhood idiopathic nephrotic syndrome (INS) may increase blood clot risk. CsA elevated coagulation markers, suggesting a potential for thromboembolic events in children with INS.

Area of Science:

  • Pediatric Nephrology
  • Hematology
  • Pharmacology

Context:

  • Idiopathic nephrotic syndrome (INS) in children often requires immunosuppressive therapy.
  • Cyclosporine A (CsA) is an effective treatment for steroid-dependent INS, but carries potential side effects.
  • The impact of CsA on coagulation in pediatric INS patients is not fully understood.

Purpose:

  • To investigate the effect of Cyclosporine A on the coagulation cascade in children with idiopathic nephrotic syndrome.
  • To assess thrombinogenesis markers (F1+2 prothrombin fragments and thrombin-antithrombin complexes) in children treated with CsA.
  • To compare coagulation activation between CsA-treated children in remission and those with INS relapse.

Summary:

  • Children with INS in remission treated with CsA showed elevated F1+2 prothrombin fragments, indicating increased coagulation activation.
  • Children with INS relapse, treated with glucocorticoids but not CsA, had F1+2 levels comparable to healthy controls.
  • Biochemical disturbances were similar in both INS groups, suggesting CsA stimulates coagulation.

Impact:

  • Cyclosporine A therapy may elevate the risk of thromboembolic events in children with idiopathic nephrotic syndrome.
  • Findings highlight the need for monitoring coagulation status in pediatric INS patients on CsA.
  • This research contributes to understanding the prothrombotic potential of CsA in pediatric nephrology.

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...